Ovid Therapeutics (OVID) Amortization of Deferred Charges (2022 - 2026)
Ovid Therapeutics' (OVID) quarterly Amortization of Deferred Charges came in at $312000.0 in Q1 2026, up 8.33% YoY from $288000.0 in Q1 2025, and up 2.3% on a QoQ basis from $305000.0 in Q4 2025.
Ovid Therapeutics (OVID) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 5 years of Amortization of Deferred Charges data on file, last reported at $312000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 8.33% year-over-year to $312000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 8.22% YoY) and the FY2025 annual result came in at $1.2 million, up 8.2% from the prior year.
- Amortization of Deferred Charges improved to $312000.0 in Q1 2026, from $305000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $354185.0 in Q2 2022 to a low of $253000.0 in Q1 2023.
- A 5-year average of $280818.8 and a median of $274500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges decreased 27.16% — and 2026, when it grew 8.33%.
- Tracing OVID's Amortization of Deferred Charges over 5 years: stood at $254970.0 in 2022, then climbed by 2.36% to $261000.0 in 2023, then grew by 8.05% to $282000.0 in 2024, then grew by 8.16% to $305000.0 in 2025, then advanced by 2.3% to $312000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $312000.0 (Q1 2026), $305000.0 (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 312,000.00 |
| Mar 31, 2026 | 312,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 294,000.00 |
| Jun 30, 2025 | 294,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | 282,000.00 |
| Dec 31, 2024 | 282,000.00 |
| Sep 30, 2024 | 277,000.00 |
| Sep 30, 2024 | 277,000.00 |
| Jun 30, 2024 | 272,000.00 |
| Jun 30, 2024 | 272,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 261,000.00 |
| Dec 31, 2023 | 261,000.00 |